BCDA

BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics and delivery systems for cardiovascular diseases. Headquartered in Sunnyvale, California, BioCardia is advancing cell and gene therapy solutions aimed at repairing damaged heart tissue, improving cardiac function, and enhancing quality of life for patients with heart failure and other cardiovascular conditions. The company combines innovative biotherapeutics with proprietary delivery technology to enable more effective treatment of heart disease. BioCardia's pipeline includes CardiAMP, an autologous cell therapy system that processes a patient's own bone marrow cells and delivers them directly to damaged heart tissue via the company's Helix biotherapeutic delivery system. The CardiAMP program has completed multiple clinical trials in patients with heart failure and ischemic heart disease, demonstrating potential for functional improvement and symptom reduction. The company is also developing CardiALLO, an allogeneic cell therapy derived from donor cells, which could provide an off-the-shelf alternative to autologous cell therapy. The company's proprietary Helix delivery platform is designed to enable precise, minimally invasive delivery of cells, genes, and other therapeutic agents directly to specific regions of the heart via catheter-based procedures. This technology aims to improve treatment efficacy while reducing procedural risks compared to surgical delivery methods. BioCardia addresses a substantial unmet medical need in heart failure, which affects millions of patients worldwide. The company continues advancing its clinical programs and exploring strategic partnerships and regulatory pathways toward commercialization of its regenerative cardiovascular therapies.